New Manufacturing Facility for Cannabis Consumables
Rob Gietl, CEO of MYM Nutraceuticals explains how their cannabis company aims to focus on the medical industry.
“MYM is a fully integrated cannabis company, with the prime directive of our business plan to be in the medical industry. We feel that that’s a longer-term play, as opposed to a recreational play. We were going off business models that we’ve seen in the U.S. and we’re here for the long-term and more stability in that category. We are doing that through a variety of different revenue streams, that we control in house ourselves. One is the development of seed and live tissue culture, which we can sell independently through a variety of different seed banks around the world and for ourselves through two things, first one is retain the quality of the product and make sure that we do not have any gaps in our production schedule. We also have a number of large grows in Canada and abroad, which we produce flower for, then we have the capability of doing extraction down to oil, for an additional revenue stream. We also have a manufacturing facility that’s on it’s final stages of completion right now that will allow us to produce final consumables in the forms of transdermal patches, pills, tinctures, things of that nature for humans. Growing on a daily basis, expanding on a daily basis, medical responses that we’re having through RND and various developments in those countries is fascinating.” – Rob Gietl, CEO of MYM Nutraceuticals
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Québec that when completed are anticipated to have over 1.5 million square feet of production space. MYM also has interest in two international cannabis production projects in Australia and Colombia. In New South Wales, Australia, the “Northern Rivers Project” is expected to have 1.2 million square feet of cannabis production space. In Medellin, Colombia, MYM and Colombia Organica are planning to build a cannabis production facility in the region. Colombia Organica currently holds a seed-to-sale license for low-THC cannabis, which permits the company to grow, produce and create cannabis derivatives to be commercialized and/or exported. Colombia Organica is in the licensing process for the cultivation and production of high-THC cannabis extracts. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.
MYM through its various joint ventures is currently building three large-scale production facilities in both Canada and Australia. Upon completion of these three projects, the total amount of greenhouse growing space is expected to exceed 2.7 million square feet.
For more information on MYM Nutraceuticals (MYM:CSE) please fill out the form below.